Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Inherited Metabolic Disease
Published in: Journal of Inherited Metabolic Disease 4/1999

01-06-1999

Recognition and management of fatty acid oxidation defects: A series of 107 patients

Authors: J. M. Saudubray, D. Martin, P. De Lonlay, G. Touati, F. Poggi-Travert, D. Bonnet, P. Jouvet, M. Boutron, A. Slama, C. Vianey-Saban, J. P. Bonnefont, D. Rabier, P. Kamoun, M. Brivet

Published in: Journal of Inherited Metabolic Disease | Issue 4/1999

Login to get access
Metadata
Title
Recognition and management of fatty acid oxidation defects: A series of 107 patients
Authors
J. M. Saudubray
D. Martin
P. De Lonlay
G. Touati
F. Poggi-Travert
D. Bonnet
P. Jouvet
M. Boutron
A. Slama
C. Vianey-Saban
J. P. Bonnefont
D. Rabier
P. Kamoun
M. Brivet
Publication date
01-06-1999
Publisher
Kluwer Academic Publishers
Published in
Journal of Inherited Metabolic Disease / Issue 4/1999
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1023/A:1005556207210

Other articles of this Issue 4/1999

Journal of Inherited Metabolic Disease 4/1999 Go to the issue

OriginalPaper

Glutaric aciduria type I: From clinical, biochemical and molecular diversity to successful therapy

OriginalPaper

Spinal muscular atrophy

OriginalPaper

A review of biochemical and molecular genetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291delC)

OriginalPaper

Neurochemistry and defects of biogenic amine neurotransmitter metabolism

OriginalPaper

The neuronal ceroid-lipofuscinoses (Batten disease): A new class of lysosomal storage diseases

OriginalPaper

Inborn errors of neurotransmitter receptors
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits